Trial Profile

A Phase 1, Open-Label, Single-Dose Pharmacokinetic Study of Lasmiditan in Pediatric Patients With Migraine

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lasmiditan (Primary)
Indications Migraine
Focus Pharmacokinetics
Sponsors Eli Lilly and Company; Eli Lilly Japan

Most Recent Events

22 Apr 2021 Results presented at the 73rd Annual Meeting of the American Academy of Neurology
10 Feb 2021 Results published in the Clinical Pharmacokinetics
04 May 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com